Logo image of CTNM

CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTNM - US21217B1008 - Common Stock

11.12 USD
+0.63 (+6.01%)
Last: 12/3/2025, 8:18:18 PM
11.12 USD
0 (0%)
After Hours: 12/3/2025, 8:18:18 PM
Fundamental Rating

3

Taking everything into account, CTNM scores 3 out of 10 in our fundamental rating. CTNM was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CTNM as it has an excellent financial health rating, but there are worries on the profitability. CTNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTNM has reported negative net income.
In the past year CTNM has reported a negative cash flow from operations.
CTNM Yearly Net Income VS EBIT VS OCF VS FCFCTNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of CTNM (-19.85%) is comparable to the rest of the industry.
With a decent Return On Equity value of -21.34%, CTNM is doing good in the industry, outperforming 65.63% of the companies in the same industry.
Industry RankSector Rank
ROA -19.85%
ROE -21.34%
ROIC N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTNM Yearly ROA, ROE, ROICCTNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

CTNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTNM Yearly Profit, Operating, Gross MarginsCTNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

CTNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTNM has more shares outstanding than it did 1 year ago.
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTNM Yearly Shares OutstandingCTNM Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
CTNM Yearly Total Debt VS Total AssetsCTNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 12.72 indicates that CTNM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.72, CTNM belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
There is no outstanding debt for CTNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.72
ROIC/WACCN/A
WACC9.06%
CTNM Yearly LT Debt VS Equity VS FCFCTNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 20.69 indicates that CTNM has no problem at all paying its short term obligations.
CTNM has a Current ratio of 20.69. This is amongst the best in the industry. CTNM outperforms 90.63% of its industry peers.
A Quick Ratio of 20.69 indicates that CTNM has no problem at all paying its short term obligations.
CTNM has a Quick ratio of 20.69. This is amongst the best in the industry. CTNM outperforms 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 20.69
Quick Ratio 20.69
CTNM Yearly Current Assets VS Current LiabilitesCTNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CTNM have decreased strongly by -341.52% in the last year.
Looking at the last year, CTNM shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.22% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.66%
EPS Next 2Y21.06%
EPS Next 3Y14.04%
EPS Next 5Y7.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTNM Yearly Revenue VS EstimatesCTNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2029 2030 2031 2032 20M 40M 60M 80M
CTNM Yearly EPS VS EstimatesCTNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CTNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTNM Price Earnings VS Forward Price EarningsCTNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTNM Per share dataCTNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as CTNM's earnings are expected to grow with 14.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.06%
EPS Next 3Y14.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTNM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTINEUM THERAPEUTICS INC-A

NASDAQ:CTNM (12/3/2025, 8:18:18 PM)

After market: 11.12 0 (0%)

11.12

+0.63 (+6.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners70.7%
Inst Owner Change24.83%
Ins Owners1.61%
Ins Owner Change0%
Market Cap324.48M
Revenue(TTM)N/A
Net Income(TTM)-42.26M
Analysts87.69
Price Target23.8 (114.03%)
Short Float %5.4%
Short Ratio8.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.96%
Min EPS beat(2)-28.28%
Max EPS beat(2)4.35%
EPS beat(4)1
Avg EPS beat(4)-172.64%
Min EPS beat(4)-656.61%
Max EPS beat(4)4.35%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.48%
PT rev (3m)2.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)10.59%
EPS NY rev (3m)9.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-2.62
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0
BVpS6.79
TBVpS6.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.85%
ROE -21.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 199.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.69
Quick Ratio 20.69
Altman-Z 12.72
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)149.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y53.66%
EPS Next 2Y21.06%
EPS Next 3Y14.04%
EPS Next 5Y7.22%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-416.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.12%
EBIT Next 3Y-46.3%
EBIT Next 5YN/A
FCF growth 1Y-276.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-269.75%
OCF growth 3YN/A
OCF growth 5YN/A

CONTINEUM THERAPEUTICS INC-A / CTNM FAQ

What is the ChartMill fundamental rating of CONTINEUM THERAPEUTICS INC-A (CTNM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTNM.


Can you provide the valuation status for CONTINEUM THERAPEUTICS INC-A?

ChartMill assigns a valuation rating of 0 / 10 to CONTINEUM THERAPEUTICS INC-A (CTNM). This can be considered as Overvalued.


Can you provide the profitability details for CONTINEUM THERAPEUTICS INC-A?

CONTINEUM THERAPEUTICS INC-A (CTNM) has a profitability rating of 1 / 10.


What is the expected EPS growth for CONTINEUM THERAPEUTICS INC-A (CTNM) stock?

The Earnings per Share (EPS) of CONTINEUM THERAPEUTICS INC-A (CTNM) is expected to grow by 53.66% in the next year.